- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Public Companies
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Mark D. Polston
News 39 results
Recognition
October 5, 2021
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2021 Guide
In the News · Source: Bloomberg Law
In the News · Source: Roll Call
September 8, 2021
Mark Polston comments on medical provider groups pressuring the Biden administration to ease the rules for a $178B COVID-19 relief fund
In the News · Source: MedCity News
August 26, 2021
Mark Polston comments on providers being required to report how they spent funding received via the CARES Act by Sept. 30
Events 27 results
Webinar
September 9, 2021
14th Annual King & Spalding Medical Device Summit
Webinar
April 29, 2021
Protecting Your CARES Act Provider Relief Funds During Audit and Enforcement: The Time to Act Is Now
Webinar
January 19, 2021
Rounding Out 2020: Overview of Recent Statutory and Regulatory Changes to Medicare and Medicaid Reimbursement
Webinar
November 10, 2020
13th Annual King & Spalding Medical Device Summit
Insights 33 results
COVID-19 Vaccine Updates
February 2, 2021
Key Insights from Leaders on the Status of Vaccine Distribution
Article · Source: Reimbursement Advisor
January 31, 2021
Telehealth Beyond the Public Health Emergency- How the delivery of remote care may change after Covid-19
Client Alert
April 14, 2020
CARES Act: Public Health and Social Services Emergency Fund
Client Alert
April 14, 2020
CARES Act: Medicare Advanced Payment Protocol